Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.39 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19542362 | 1.00 | EPHX2 (0.64) | EPHX2KDM4ETSHRHTTMAOA | |
| SCHEMBL23641349 | 1.00 | EPHX2 (0.64) | EPHX2KDM4ETSHRHTTMAOA | |
| SCHEMBL645409 | 0.98 | EPHX2 (0.62) | EPHX2KDM4ETSHRHTTMAOA | |
| SCHEMBL16111819 | 0.87 | EPHX2 (0.73) | EPHX2KDM4ETSHRMAPT | |
| SCHEMBL16111818 | 0.87 | EPHX2 (0.73) | EPHX2KDM4ETSHRMAPT | |
| SCHEMBL22623764 | 0.84 | TSHR (0.53) | EPHX2KDM4ETSHRHTTMAOA | |
| SCHEMBL11169825 | 0.84 | TSHR (0.53) | EPHX2KDM4ETSHRHTTMAOA | |
| SCHEMBL4653040 | 0.83 | EPHX2 (0.69) | EPHX2TSHRMAPTDAGLA | |
| SCHEMBL13295596 | 0.83 | EPHX2 (0.69) | EPHX2TSHRMAPTDAGLA | |
| SCHEMBL3294148 | 0.83 | EPHX2 (0.69) | EPHX2TSHRMAPTDAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019026-B1 | Modulators of Protein Tyrosine Phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2006-03-28 | — | — | US | claimed |
| EP-1214325-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK AS (DK) | 2005-11-09 | — | — | EP | claimed |
| EP-1214325-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2002-06-19 | — | — | EP | claimed |
| WO-2001019831-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2001-03-22 | — | — | WO | claimed |
| US-10927155-B2 | Dual inhibitory action peptidomimetic inhibitor for IL-33 and IL-1beta | George Mason Research Foundation, Inc. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190352351-A1 | DUAL INHIBITORY ACTION PEPTIDOMIMETIC INHIBITOR FOR IL-33 AND IL-1BETA | George Mason Research Foundation, Inc. | 2019-11-21 | — | — | US | disclosed |
| US-10316167-B2 | Oxygen scavengers, compositions comprising the scavengers, and articles made from the compositions | PLASTIPAK PACKAGING (US) | 2019-06-11 | — | — | US | disclosed |
| US-10294222-B2 | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180057490-A1 | BENZOMORPHOLINE AND BENZOMORPHOLINE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2018-03-01 | — | — | US | disclosed |
| US-7019026-B1 | Modulators of Protein Tyrosine Phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2006-03-28 | — | — | US | disclosed |
| EP-1214325-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK AS (DK) | 2005-11-09 | — | — | EP | disclosed |
| EP-1214325-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001019831-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057490-A1 | BENZOMORPHOLINE AND BENZOMORPHOLINE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | GRM4, GRM1, GRIA4 | EPHX2 4095/4885KDM4E 1404/4885TSHR 513/4885 |
| US-10316167-B2 | Oxygen scavengers, compositions comprising the scavengers, and articles made from the compositions | PRDX5, LPO, CAT | EPHX2 969/4885KDM4E 4201/4885TSHR 3903/4885 |
| US-10927155-B2 | Dual inhibitory action peptidomimetic inhibitor for IL-33 and IL-1beta | IL33, IL1R1, IL1RN | EPHX2 1209/4885KDM4E 4645/4885TSHR 801/4885 |
| US-20190352351-A1 | DUAL INHIBITORY ACTION PEPTIDOMIMETIC INHIBITOR FOR IL-33 AND IL-1BETA | IL33, IL1R1, IL1RN | EPHX2 1209/4885KDM4E 4645/4885TSHR 801/4885 |
| US-10294222-B2 | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | GRM4, GRM1, GRIA4 | EPHX2 4095/4885KDM4E 1404/4885TSHR 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.